LONDON, August 7, 2014 /PRNewswire/ --

On Wednesday, August 06, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average finished the day 0.08% higher at 16,443.34, and the S&P 500 closed flat at 1,920.24. However the gains were not broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, and the index has declined 2.91% in the last one month. Investor-Edge has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Sangamo BioSciences Inc. (NASDAQ: SGMO), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Dyax Corporation (NASDAQ: DYAX). Free research on these five companies can be accessed at:

http://investor-edge.com/register

On Wednesday, BioMarin Pharmaceutical Inc.'s stock recorded a trading volume of 0.99 million shares, lower than its three months average volume of 1.25 million shares. The stock finished the day at $65.11, up 0.23%, and registered an intraday range of $64.18 and $65.49. Shares of BioMarin Pharmaceutical Inc. have advanced 0.81% in the last one month and 10.73% in the past three months. However, the stock has declined 7.45% on YTD basis. Furthermore, the stock is trading above its 50-day moving average. The stock's 200-day moving average of $66.28 is above its 50-day moving average of $61.09. Additionally, shares of BioMarin Pharmaceutical Inc. have a Relative Strength Index (RSI) of 65.01. Sign up and read the free notes on BMRN at:

http://www.Investor-Edge.com/BMRN-07Aug2014

Merrimack Pharmaceuticals Inc.'s stock gained 0.51%, to close Wednesday's session at $5.96, after oscillating between $5.88 and $6.05. The stock recorded a trading volume of 0.77 million shares, below its three months average volume of 1.74 million shares. Over the past three trading sessions and from the beginning of 2014, Merrimack Pharmaceuticals Inc.'s shares have gone up 3.11% and 11.80%, respectively. However, over the last one month, the stock has fallen by 20.11%. The company's shares are trading above their 200-day moving average. The stock's 50-day moving average of $6.98 is above its 200-day moving average of $5.43. Further, Merrimack Pharmaceuticals Inc.'s stock has an RSI of 41.02. The complimentary notes on MACK can be downloaded as in PDF format at:

http://www.Investor-Edge.com/MACK-07Aug2014

On Wednesday, shares in Sangamo BioSciences Inc. finished the session 2.21% lower at $13.30. A total of 0.67 million shares were traded, which was below its three months average volume of 0.88 million shares. The stock moved between $13.14 and $13.71 during the session. Over the past three trading sessions and last three months, Sangamo BioSciences Inc.'s shares have surged 7.87% and 2.94%, respectively. However, the stock has lost 4.25% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $14.98 is greater than its 50-day moving average of $14.11. Shares of Sangamo BioSciences Inc. have an RSI of 53.24. Register for free on Investor-Edge and access the latest research on SGMO at:

http://www.Investor-Edge.com/SGMO-07Aug2014

ZIOPHARM Oncology Inc.'s stock fluctuated between $3.12 and $3.27 before ending Wednesday's session up 2.54%, at $3.23. The stock reported a trading volume of 0.32 million shares, below its three months average volume of 0.79 million shares. Further, ZIOPHARM Oncology Inc.'s shares have gained 7.67% over the past three trading sessions. However, the stock has plummeted 19.45% over the last one month and 25.58% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $3.94 is greater than its 50-day moving average of $3.69. Moreover, shares of ZIOPHARM Oncology Inc. have an RSI of 40.36. The complete research on ZIOP is available for free at:

http://www.Investor-Edge.com/ZIOP-07Aug2014

Dyax Corp.'s stock fell by 1.27%, to close Wednesday's session at $9.33, after vacillating between $9.24 and $9.54. The stock recorded a trading volume of 0.97 million shares, below its three months average volume of 1.23 million shares. Over the last one month, Dyax Corp.'s shares have fallen by 5.28%. However, over the past three months and from the beginning of 2014, the stock has rallied 47.16% and 23.82%, respectively. The company's shares are trading above their 50-day and 200-day moving averages. The stock's 50-day moving average of $8.81 is above its 200-day moving average of $8.29. Further, Dyax Corp.'s stock has an RSI of 56.26. Free in depth research on DYAX is available at:

http://www.Investor-Edge.com/DYAX-07Aug2014

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

Investor-Edge.com

SOURCE Investor-Edge